cdp323 (biogen Search Results


cdp 323  (Biogen Inc)
90
Biogen Inc cdp 323
Main industry-sponsored studies for oral NME currently in development for multiple sclerosis
Cdp 323, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdp 323/product/Biogen Inc
Average 90 stars, based on 1 article reviews
cdp 323 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Main industry-sponsored studies for oral NME currently in development for multiple sclerosis

Journal: mAbs

Article Title: Monoclonal antibody therapy in multiple sclerosis

doi: 10.4161/mabs.2.6.13270

Figure Lengend Snippet: Main industry-sponsored studies for oral NME currently in development for multiple sclerosis

Article Snippet: CDP 323 , Phase 2 terminated , {"type":"clinical-trial","attrs":{"text":"NCT00484536","term_id":"NCT00484536"}} NCT00484536 , Biogen Idec UCB , p.o. , Integrin alpha4 antagonist , Placebo , RMS.

Techniques: